Top

Supportive Care in Cancer

Published in:

01-05-2020 | Multiple Myeloma | Original Article

The importance of physical function in patients with multiple myeloma for improving quality of life

Authors: Shin Hoo Kim, Inho Kim, Youngil Koh, Dongyeop Shin, Joonsik Hong, Kwan Sik Seo

Published in: Supportive Care in Cancer | Issue 5/2020

Abstract

Purpose

To investigate the relationship between physical function and quality of life in multiple myeloma patients.

Methods

In this retrospective cross-sectional study, data from patients with multiple myeloma (N = 63), who were referred to the department of Rehabilitation Medicine from October 2017 to May 2018, were reviewed. Patients were excluded based on the following criteria: acute illness, unstable medical conditions, impaired cognition or communication, refusal, or inability to perform the assessment. Physical function was evaluated with the Mini-Balance Evaluation Systems Test (Mini-BESTest), and the European Organization for Research and Treatment of Cancer questionnaires QLQ-C30 and QLQ-MY20 were used for the evaluation of quality of life. To evaluate fatigue and psychotic status, the Fatigue Severity Scale and Beck Depression Inventory were used. Patients were divided into two groups (“good-function group” and “poor-function group”), based on previously studied normative values of the Mini-BESTest. Clinical data was reviewed to interrogate the contributing factors of physical function.

Results

Positive correlations were observed between Mini-BESTest scores and all domains of the QLQ-C30. The Mini-BESTest score was lower in patients with lower serum hemoglobin (r = 0.396, p = 0.001) and albumin levels (r = 0.440, p < 0.001), severe disease-related symptoms (r = − 0.39, p = 0.02), and depression (r = − 0.538, p < 0.001). Further, the poor-function group showed lower hemoglobin (p = 0.024) and albumin levels (p = 0.004).

Conclusion

In patients with multiple myeloma, physical function had a significant relationship with quality of life. Low hemoglobin and albumin levels, severe disease- or treatment-related symptoms, and depression were related to decreased physical function, and thus consequentially exert an effect on quality of life in multiple myeloma patients.

Sherman A, Simonton S, Latif U, Spohn R, Tricot G (2004) Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation. Bone Marrow Transplant 33(9):955–962CrossRef

Poulos AR, Gertz MA, Pankratz S, Post-White J (2001) Pain, mood disturbance, and quality of life in patients with multiple myeloma. Oncol Nurs Forum 28(7):1163–1171PubMed

Robinson D Jr, Esseltine DL, Regnault A, Meunier J, Liu K, van de Velde H (2016) The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials. Br J Haematol 174(3):368–381CrossRef

Vogl DT, Delforge M, Song K, Guo S, Gibson CJ, Ervin-Haynes A, Facon T (2018) Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone. Leuk Lymphoma 59(2):398–405CrossRef

Coleman EA, Goodwin JA, Coon SK, Richards K, Enderlin C, Kennedy R, Stewart CB, McNatt P, Lockhart K, Anaissie EJ, Barlogie B (2011) Fatigue, sleep, pain, mood, and performance status in patients with multiple myeloma. Cancer Nurs 34(3):219–227CrossRef

Dimeo F, Schmittel A, Fietz T, Schwartz S, Kohler P, Boning D, Thiel E (2004) Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment. Ann Oncol 15(8):1237–1242CrossRef

Franchignoni F, Horak F, Godi M, Nardone A, Giordano A (2010) Using psychometric techniques to improve the balance evaluation systems test: the mini-BESTest. J Rehabil Med 42(4):323–331CrossRef

Rome SI, Jenkins BS, Lilleby KE (2011) Mobility and safety in the multiple myeloma survivor: survivorship care plan of the International Myeloma Foundation nurse leadership board. Clin J Oncol Nurs 15(4):41–52CrossRef

Delforge M, Bladé J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, Palumbo A, Van Damme P, San-Miguel JF, Sonneveld P (2010) Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 11(11):1086–1095CrossRef

10.

O’Hoski S, Winship B, Herridge L, Agha T, Brooks D, Beauchamp MK, Sibley KM (2014) Increasing the clinical utility of the BESTest, mini-BESTest, and brief-BESTest: normative values in Canadian adults who are healthy and aged 50 years or older. Phys Ther 94(3):334–342CrossRef

11.

Yun YH, Park YS, Lee ES, Bang S-M, Heo DS, Park S, You C, West K (2004) Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res 13(4):863–868CrossRef

12.

Cocks K, Cohen D, Wisløff F, Sezer O, Lee S, Hippe E, Gimsing P, Turesson I, Hajek R, Smith A (2007) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 43(11):1670–1678CrossRef

13.

Fayers P, Bottomley A, Group EQoL (2002) Quality of life research within the EORTC—the EORTC QLQ-C30. Eur J Cancer 38:125–133CrossRef

14.

Stone P, Richards M, A’hern R, Hardy J (2000) A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 11(5):561–567CrossRef

15.

Mystakidou K, Tsilika E, Parpa E, Smyrniotis V, Galanos A, Vlahos L (2007) Beck depression inventory: exploring its psychometric properties in a palliative care population of advanced cancer patients. Eur J Cancer Care 16(3):244–250CrossRef

16.

Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5(3):224–237CrossRef

17.

Black SA, Rush RD (2002) Cognitive and functional decline in adults aged 75 and older. J Am Geriatr Soc 50(12):1978–1986CrossRef

18.

Jørgensen TL, Hallas J, Friis S, Herrstedt J (2012) Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer 106(7):1353–1360CrossRef

19.

Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78(1):21–33CrossRef

20.

Mittelman M (2003) The implications of anemia in multiple myeloma. Clin Lymphoma 4(Suppl 1):S23–S29CrossRef

21.

Bladé J, Rosiñol L (2005) Renal, hematologic and infectious complications in multiple myeloma. Best Pract Res Clin Haematol 18(4):635–652CrossRef

22.

Curt GA (2000) The impact of fatigue on patients with cancer: overview of FATIGUE 1 and 2. Oncol Suppl 2:9–12

23.

Birgegård G, Gascón P, Ludwig H (2006) Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol 77(5):378–386CrossRef

24.

Kim JE, Yoo C, Lee DH, Kim SW, Lee JS, Suh C (2010) Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. Ann Hematol 89(4):391–397CrossRef

25.

Greipp PR, Miguel JS, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412–3420CrossRef

26.

Sullivan DH (2001) Guest editorial: what do the serum proteins tell us about our elderly patients? J Gerontol A Biol Sci Med Sci 56(2):M71–M74CrossRef

27.

Rummans TA, Frost M, Suman VJ, Taylor M, Novotny P, Gendron T, Johnson R, Hartmann L, Dose AM, Evans RW (1998) Quality of life and pain in patients with recurrent breast and gynecologic cancer. Psychosomatics 39(5):437–445CrossRef

28.

Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manag 13(2):63–74CrossRef

29.

Paice JA (2004) Assessment of symptom clusters in people with cancer. J Natl Cancer Inst Monogr 32:98–102CrossRef

30.

Gaston-Johansson F, Fall-Dickson JM, Bakos AB, Kennedy MJ (1999) Fatigue, pain, and depression in pre-autotransplant breast cancer patients. Cancer Pract 7(5):240–247CrossRef

31.

Alacacioglu A, Binicier O, Gungor O, Oztop I, Dirioz M, Yilmaz U (2010) Quality of life, anxiety, and depression in Turkish colorectal cancer patients. Support Care Cancer 18(4):417–421CrossRef

32.

Mohan A, Singh P, Singh S, Goyal A, Pathak A, Mohan C, Guleria R (2007) Quality of life in lung cancer patients: impact of baseline clinical profile and respiratory status. Eur J Cancer Care (Engl) 16(3):268–276CrossRef

33.

O'Brien BJ, Buxton MJ, Patterson DL (1993) Relationship between functional status and health-related quality-of-life after myocardial infarction. Med Care 31(10):950–955CrossRef

34.

Young-McCaughan S, Arzola SM (2007) Exercise intervention research for patients with cancer on treatment. Semin Oncol Nurs 23(4):264–274CrossRef

35.

Headley JA, Ownby KK, John LD (2004) The effect of seated exercise on fatigue and quality of life in women with advanced breast cancer. Oncol Nurs Forum 31(5):977–983CrossRef

36.

Anderson KC, Kyle RA, Dalton WS, Landowski T, Shain K, Jove R, Hazlehurst L, Berenson J (2000) Multiple myeloma: new insights and therapeutic approaches. Hematol Am Soc Hematol Educ Program 2000(1):147–165CrossRef

37.

Rajkumar SV (2016) Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 91(7):719–734CrossRef

38.

Groeneveldt L, Mein G, Garrod R, Jewell AP, Van Someren K, Stephens R, D’Sa SP, Yong KL (2013) A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors. BMC Cancer 13. https://doi.org/10.1186/1471-2407-13-31

39.

de Morton NA, Davidson M, Keating JL (2010) Validity, responsiveness and the minimal clinically important difference for the de Morton Mobility Index (DEMMI) in an older acute medical population. BMC Geriatr 10. https://doi.org/10.1186/1471-2318-10-72

40.

MacKnight C, Rockwood K (2000) Rasch analysis of the hierarchical assessment of balance and mobility (HABAM). J Clin Epidemiol 53(12):1242–1247CrossRef

Title: The importance of physical function in patients with multiple myeloma for improving quality of life
Authors: Shin Hoo Kim
Inho Kim
Youngil Koh
Dongyeop Shin
Joonsik Hong
Kwan Sik Seo
Publication date: 01-05-2020
Publisher: Springer Berlin Heidelberg
Keywords: Multiple Myeloma
Fatigue
Published in: Supportive Care in Cancer / Issue 5/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-05054-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2020

Correction to: Influence of cancer and acute inflammatory disease on taste perception: a clinical pilot study

Knowledge matters and empowers: HPV vaccine advocacy among HPV-related cancer survivors

Preoperative rehabilitation for patients undergoing colorectal cancer surgery: a retrospective cohort study

Depomedroxyprogesterone acetate therapy for hot flashes in survivors of breast cancer: no unfavorable impact on recurrence and survival

Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines

Quality improvement in sexual health care for oncology patients: a Canadian multidisciplinary clinic experience

Keynote webinar | Spotlight on antibody–drug conjugates in cancer